Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: An European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study

Gelderblom, H.; Blay, J.Y.; Seddon, B.M.; Leahy, M.; Ray-Coquard, I.; Sleijfer, S.; ... ; Hohenberger, P. (2014)

Article / Letter to editor

• Randomised phase II study
• GST
• Brostallicin
• Doxorubicin
• Soft tissue sarcoma

• All authors: Gelderblom, H.; Blay, J.Y.; Seddon, B.M.; Leahy, M.; Ray-Coquard, I.; Sleijfer, S.; Kerst, J.M.; Rutkowski, P.; Bauer, S.; Ouali, M.; Marreaud, S.; Straaten, R.J.H.M. van der; Guchelaar, H.J.; Weitman, S.D.; Hogendoorn, P.C.W.; Hohenberger, P.
• Date: 2014-01-31
• Journal: European Journal of Cancer
• Volume: 50
• Issue: 2
• Pages: 388 - 396
• DOI: doi:10.1016/j.ejca.2013.10.002